Active RFPs
20
N/A
CDMO pipeline includes 20 active RFPs, with 6 high-conviction phase 3 programs including GLP-1 candidates.
BLUEJETHEALTHCARE
Healthcare
15 Jan 2026
Blue Jet Healthcare Ltd — Q3 FY26
Blue Jet Healthcare reported a sharp 40% YoY decline in Q3 FY26 revenue to ₹192.4 crore, with EBITDA down 62% and PAT down 39%, driven by destocking in the key pharma intermediate (bempedoic acid) and supply chain realignment.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Blue Jet Healthcare reported a sharp 40% YoY decline in Q3 FY26 revenue to ₹192.4 crore, with EBITDA down 62% and PAT down 39%, driven by destocking in the key pharma intermediate (bempedoic acid) and supply chain realignment. Contrast media revenue was flat sequentially despite strong dispatches, with goods-in-transit normalization expected in Q4. Gross margin contracted to 52% due to product mix and a 1% inventory write-off. Management guided that destocking may persist for another quarter or two, but remains confident in FY27 recovery backed by three large contrast media molecules (NC intermediate, iodinated product, backward integration unit) and a ₹1,000 crore greenfield capex at Visakhapatnam. Key risk: the bempedoic acid supply chain realignment could lead to permanent volume loss if the innovator shifts share to new suppliers.
Key Numbers
Cash and cash equivalents
₹410 Cr
N/A
Company has ₹410 crore cash as of Dec 2025 to fund capex without immediate debt.
Gross margin (9M FY26)
53%
-200bps YoY
Gross margin for 9M FY26 was 53% vs 55% in 9M FY25, impacted by product mix and inventory write-off.
Power from renewables
70%
N/A
70% of power consumption met through wind and solar, supporting sustainability goals.
Management Guidance
Unit 3 backward integration plant ready for validation in Q1 FY27
The new block for contrast media intermediates is nearing completion and expected to be ready for qualification in Q1 FY27, improving cost competitiveness.
Management guidance expansionVisakhapatnam greenfield capex of ₹1,000 crore over 3-4 years
Board-approved ₹1,000 crore investment for a greenfield site, with phase one dedicated to API and intermediates aligned with customer demand.
Management guidance capexHyderabad R&D center operational from Q3 FY27
Lease secured for R&D activities in Hyderabad; development work expected to commence from Q3 FY27, focusing on GLP-1 intermediates, peptide chemistry, and biocatalysis.
Management guidance expansionNew artificial sweetener exhibit batches in FY27
Exhibit batches of a new artificial sweetener will be initiated in FY27, complementing the existing high-intensity sweetener portfolio.
Management guidance growthKey Risks
Bempedoic acid supply chain realignment may reduce volumes
Management acknowledged destocking and supply chain realignment for bempedoic acid, but did not quantify the impact or confirm when volumes will normalize. Analyst raised concern about potential permanent loss of market share.
high · analyst_questionGross margin volatility from product mix and inventory write-offs
Gross margin fell to 52% in Q3 due to product mix and a 1% inventory write-off. Management guided a wide 50-55% range, indicating uncertainty.
medium · data_observationHigh customer concentration in pharma intermediates
Despite diversification efforts, a significant portion of revenue still depends on a few molecules, making the company vulnerable to order lumpiness.
medium · analyst_questionCapex execution and funding risk for ₹1,000 crore Visakhapatnam project
The large greenfield capex may strain cash flows; management mentioned options including debt or equity dilution, but no firm plan was provided.
medium · analyst_questionNotable Quotes
We believe the scale, infrastructure and the geographic advantage of VISAC will strengthen positioning as a reliable global partner in complex chemistries.
These are very sticky relations and in most of these cases these are backed by multi-year supply agreements.
We have been supplying we have supplied large quantities in the past... huge quantities have been supplied by us in the past and um uh so that's the momentum that I'm talking about.
Frequently Asked Questions
What was Blue Jet Healthcare's revenue in Q3 FY26?
Blue Jet Healthcare reported revenue of ₹192 Cr in Q3 FY26, representing a -40% change compared to the same quarter last year.
What guidance did Blue Jet Healthcare management give for FY27?
Unit 3 backward integration plant ready for validation in Q1 FY27: The new block for contrast media intermediates is nearing completion and expected to be ready for qualification in Q1 FY27, improving cost competitiveness. Visakhapatnam greenfield capex of ₹1,000 crore over 3-4 years: Board-approved ₹1,000 crore investment for a greenfield site, with phase one dedicated to API and intermediates aligned with customer demand. Hyderabad R&D center operational from Q3 FY27: Lease secured for R&D activities in Hyderabad; development work expected to commence from Q3 FY27, focusing on GLP-1 intermediates, peptide chemistry, and biocatalysis. New artificial sweetener exhibit batches in FY27: Exhibit batches of a new artificial sweetener will be initiated in FY27, complementing the existing high-intensity sweetener portfolio.
What are the key risks for Blue Jet Healthcare in FY27?
Key risks include Bempedoic acid supply chain realignment may reduce volumes — Management acknowledged destocking and supply chain realignment for bempedoic acid, but did not quantify the impact or confirm when volumes will normalize. Analyst raised concern about potential permanent loss of market share.; Gross margin volatility from product mix and inventory write-offs — Gross margin fell to 52% in Q3 due to product mix and a 1% inventory write-off. Management guided a wide 50-55% range, indicating uncertainty.; High customer concentration in pharma intermediates — Despite diversification efforts, a significant portion of revenue still depends on a few molecules, making the company vulnerable to order lumpiness.; Capex execution and funding risk for ₹1,000 crore Visakhapatnam project — The large greenfield capex may strain cash flows; management mentioned options including debt or equity dilution, but no firm plan was provided..
Did Blue Jet Healthcare meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Blue Jet Healthcare Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.